DexTech closes research agreement on glycosylation technology

Press release 2015-11-02

DexTech Medical AB, 556664-6203

DexTech closes research agreement on glycosylation technology

DexTech announced today that Roche and DexTech have signed a research agreement with the aim to share DexTech’s know-how and proprietary glycosylation technology for applications in one of Roche’s oncology projects based on monoclonal antibodies. DexTech owns two globally granted patents relating to electrostatically modified dextrans for applications in cancer treatment. Roche will fund the research with EUR 50,000 and the agreement runs for 12 months with possibility for extension.

”We are very happy to collaborate with Roche and bring in our our expertise/technology into one of their oncology projects. We see this as an acknowledgement of the possibilities with DexTech’s technology in cancer treatment,” says DexTech’s CEO Anders R Holmberg.

For additional information

Gösta Lundgren – Investor Relations
DexTech Medical AB
Telephone: +46 (0) 707104788
E-mail: gosta.lundgren@dextechmedical.com